Catalyst Biosciences Inc. (CBIO) shares had surged in the current trading session by 5.29% mark to the price of $4.78 at which it traded at last check. CBIO stock had previously the session on Monday at the price of $4.54. The CBIO stock volume traded 4,363,165shares. In the past year up to date, CBIO stock have shed by -27.59% and in the past week, the shares moved up by 4.85%. In the past three and six months, the stock has shed -11.84%, and -30.05%. Furthermore, Catalyst Biosciences Inc. is currently valued in the market at $133.52 million and has 28.39 million outstanding shares.
Here’s what you need to know about Catalyst Biosciences Inc.
Catalyst Biosciences Inc. is a biotechnology company that is specifically a clinical-stage biopharmaceutical focusing on the development and discovery of new molecules for treatment and therapeutics. The company specifically focuses on developing treatment for hemostasis and complement regulation fields through protease product candidates. The proteases are engineered to treat diseases that are caused due to dysregulation of coagulation cascades as well as complement cascades. The company has collaborated with several companies to go along with the projects in its pipeline including a preclinical program that is being done in collaboration with Biogen International GmbH for the purpose of finding treatment for age-related macular degeneration (AMD). Furthermore, it has a partnership with Mosaic Biosciences Inc. that is strategically established to develop products of intravitreal anti-complement factor 3 attributes in order to treat the dry age-related Macular Degeneration as well as retinal diseases. Catalyst Biosciences Inc.’s origin is from 2002 and is based in South San Francisco, California.
Another milestone in MarzAAclinicaly clinical trial achieved by Catalyst Biosciences
One of the most effective approvals for pacing up and accelerating the clinical trial, testing, and approval of a drug or a treatment in the US Food and Drug Association is to be granted the Fast Track Designation by the FDA. This approval is usually requested and sought by clinical-testing biotechnology companies for unmet medical need required for serious or debilitating conditions. Today on 28th June 2021, Catalyst Biosciences Inc. has announced that is has been granted as such Fast Track Designation by the FDA for the treatment of episodic bleeding in subjects due to Factor VII deficiency. The treatment is known as Marzeptacogalfa (activated) which is administered through next-generation engineered coagulation Factor VIIa subcutaneously.
Catalyst Biosciences Inc. is currently running two trials along one another. One of the trials is a phase 1/2 open-lab study for which patients are being enrolled who have FVII deficiency and the second is phase 3 trial which is ongoing for the patients with hemophilia A and B that are being treated with inhibitors for episodic bleeding to evaluate MarzAA.
This is a very significant development in the trial and approval of MarzAA and related progress. Investors are hinging on investment in CBIO stock due to the attractive potential MarzAA can bring to the share price and stock of the company once it has granted approval or keeps hitting milestones.
